Quick Takeaways
- ARCH Venture Fund IX, L.P. filed SCHEDULE 13G/A for Sana Biotechnology, Inc. Common Stock, par value $0.0001 per share (SANA).
- Disclosed ownership: 17%.
- Date of event: 30 Sep 2025.
ARCH Venture Fund IX, L.P. - 30 Sep 2025 SCHEDULE 13G/A Report for Sana Biotechnology, Inc. Common Stock, par value $0.0001 per share (SANA)
- Filing Manager
- ARCH Venture Fund IX, L.P.
- Reporting Manager
- Robert Nelsen
- Symbol
- SANA
- Shares outstanding
- 266,434,249 shares
- Disclosed Ownership
- 46,093,125 shares
- Ownership
- 17%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 16:30:04 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ARCH Venture Fund IX, L.P. disclosed 17% ownership in Sana Biotechnology, Inc. Common Stock, par value $0.0001 per share (SANA) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 16:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (15)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners IX, L.P. | its General Partner | |
| ARCH Venture Fund IX Overage, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners IX Overage, L.P. | its General Partner | |
| ARCH Venture Fund X, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners X, L.P. | its General Partner | |
| ARCH Venture Fund X Overage, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners X Overage, L.P. | its General Partner | |
| ARCH Venture Partners IX, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners IX, LLC | its General Partner | |
| ARCH Venture Partners IX Overage, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners IX, LLC | its General Partner | |
| ARCH Venture Partners X Overage, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners X, LLC | its General Partner | |
| ARCH Venture Partners X, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners X, LLC | its General Partner | |
| ARCH Venture Partners IX, LLC | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director | |
| ARCH Venture Partners X, LLC | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director | |
| Keith Crandell | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Keith Crandell | |
| Clinton Bybee | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Clinton Bybee | |
| Robert Nelsen | 17% | 46,093,125 | 232,444 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Robert Nelsen | |
| Steven Gillis | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Steven Gillis | |
| Kristina Burow | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Kristina Burrow |